vGRID SBRTNCT05727787
vGRID SBRT: A Phase I Clinical Trial in Unresectable or Metastatic HCC
StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
At risk: Primary completion moved 2 years later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Aug 31, 2026 to Aug 31, 2028
- Eligibility criteria expanded, about 18 words
- Notable Primary completion date: May 28, 2025 to Aug 31, 2026
- Study completion date: Dec 28, 2025 to Aug 31, 2028
- Minor Primary completion date: Feb 28, 2025 to May 28, 2025
- Study completion date: Feb 28, 2025 to Dec 28, 2025
- Notable Eligibility criteria shortened, about 173 wordsv3
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
- Eligibility criteria expanded, about 246 words
- Start date changed from estimate of Feb 20, 2023 to Feb 23, 2023
- Site details revised
- Study title expanded, about 2 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum tolerated dose (MTD) of Single Fraction GRID SBRT
Timeframe: First day of post-GRID SBRT through 3 month post-radiation
Secondary (5)
Local control utilizing RECIST v1.1 for HCC.
Regional failure utilizing RECIST v1.1 for HCC.
Progression free survival (PFS)
Time to Progression (TTP)
Molecular correlatives: TCR repertoire analysis.
Arms and interventions
Single fraction SBRT 27 GyExperimental
vGRID SBRT 3+3 dose escalation, single fraction, one day cycle length
Radiation: Stereotactic Body Radiation Treatment
Sites
1 site in 1 country
- University of Kansas Medical CenterKansas City, Kansas, United States